



MAY 2 5 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Kerry Anne Kahn Regulatory Affairs Coordinator R-Group International, Inc. 2321 N.W. 66<sup>th</sup> Ct., Suite W-4 Gainesville, FL 32653 Re: K993777

Disposable Ball and Loop Electrodes

Dated: February 25, 2000 Received: February 25, 2000

Regulatory Class: II

21 CFR §884.4120/Procode: 85 HGI

## Dear Ms. Kahn:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours

Daniel G. Schultz, M.D.

Captain, USPHS

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation Center for Devices and Radiological Health

Enclosure(s)

## Statement of Intended Use

The loop electrodes are designed for the LEEP or LLETZ procedure, which is performed to remove a lesion of abnormal cells from the cervix. The loop electrode is attached to an electrosurgical generator that emits an electrical current used to cut away the affected tissue. Following the removal of the cells in the affected area the ball electrode is used to seal the area and stop any bleeding that may have occurred.  Some indications for use are:  a. Cervical conizations  b. Large Loop Excision of the Transformation Zone (LLETZ) in the Diagnosis and Treatment of some Cervical Intraepithelial Neoplasias (CIN) and Dysplasias.  c. External Anogenital Lesions  d. Large Vaginal Intraepithelial Neoplasic (VAIN) Lesions.  (Please do not write below this line-continue on another page if needed.)  Concurrence of CDRH, Office of Device Evaluation (ODE)  Prescription Use:  OR  Over-the-Counter Use: (Optional Format 1-2)  (Division Sign-Off)  Division of Reproductive, Abdominal, ENT.	510(k) Number (if known):] Device Name:Disposable Ball Indications for Use:	K993777 and Loop Electrode		
a. Cervical conizations b. Large Loop Excision of the Transformation Zone (LLETZ) in the Diagnosis and Treatment of some Cervical Intraepithelial Neoplasias (CIN) and Dysplasias. c. External Anogenital Lesions d. Large Vaginal Intraepithelial Neoplasic (VAIN) Lesions.  (Please do not write below this line-continue on another page if needed.)  Concurrence of CDRH, Office of Device Evaluation (ODE)  Prescription Use:  OR Over-the-Counter Use: (Optional Format 1-2)	to remove a lesion of abnormal of electrosurgical generator that em tissue. Following the removal of	ells from the cervix. The sits an electrical current u f the cells in the affected	sed to cut away the affected area the ball electrode is used to	
a. Cervical conizations b. Large Loop Excision of the Transformation Zone (LLETZ) in the Diagnosis and Treatment of some Cervical Intraepithelial Neoplasias (CIN) and Dysplasias. c. External Anogenital Lesions d. Large Vaginal Intraepithelial Neoplasic (VAIN) Lesions.  (Please do not write below this line-continue on another page if needed.)  Concurrence of CDRH, Office of Device Evaluation (ODE)  Prescription Use:  OR Over-the-Counter Use: (Optional Format 1-2)	Some indications for use are:			
d. Large Vaginal Intraepithelial Neoplasic (VAIN) Lesions.  (Please do not write below this line-continue on another page if needed.)  Concurrence of CDRH, Office of Device Evaluation (ODE)  Prescription Use:  (Per 21 CFR 801.109)  OR  Over-the-Counter Use: (Optional Format 1-2)	a. b.	Large Loop Excision of (LLETZ) in the Diagno Cervical Intraepithelial Dysplasias.	sis and Treatment of some Neoplasias (CIN) and	
Concurrence of CDRH, Office of Device Evaluation (ODE)  Prescription Use:  (Per 21 CFR 801.109)  OR  Over-the-Counter Use:  (Optional Format 1-2)  One  (Division Sign-Off)	d.		helial Neoplasic (VAIN)	
Concurrence of CDRH, Office of Device Evaluation (ODE)  Prescription Use:  (Per 21 CFR 801.109)  OR  Over-the-Counter Use:  (Optional Format 1-2)  One  (Division Sign-Off)				
Concurrence of CDRH, Office of Device Evaluation (ODE)  Prescription Use:  (Per 21 CFR 801.109)  OR  Over-the-Counter Use:  (Optional Format 1-2)  One  (Division Sign-Off)				
Concurrence of CDRH, Office of Device Evaluation (ODE)  Prescription Use:  (Per 21 CFR 801.109)  OR  Over-the-Counter Use:  (Optional Format 1-2)  One  (Division Sign-Off)		•		
Prescription Use: OR Over-the-Counter Use: (Optional Format 1-2)  OR Over-the-Counter Use: (Optional Format 1-2)	(Please do not write below this line-continue on another page if needed.)			
(Per 21 CFR 801.109)  (Optional Format 1-2)  (Division Sign-Off)	Concurrence of CDRH, Office of Device Evaluation (ODE)			
(Division Sign-Off)  Division of Reproductive, Abdominal, ENT.	Prescription Use: (Per 21 CFR 801.109)	OR		
Division Sign-Off) V Division of Reproductive, Abdominal, ENT	Division Sign OSS			
	Divi	ision of Reproductive, Abdom	ninal, ENT.	

and Radiological Devices

510(k) Number\_\_\_\_